Weekly Market Pulse · extended edition · week of August 3–7, 2026 · published Saturday, August 8

Weekly Market Pulse

The economy lost jobs in July and the market had its best week since April. That is not a contradiction: with a Federal Reserve whose internal debate is about whether to raise rates rather than cut them, a payroll report of minus 23,000 removes the tail risk the market had been pricing all summer. The S&P 500 closed at a record, the Nasdaq gained more than 5%, crude gave back roughly a tenth of its value on the Iran diplomatic opening, and gold, silver, uranium and rare earths all outran the index. The week ahead brings the July CPI on Wednesday and the July PPI on Thursday, which is where the other half of the argument gets settled.

July payrolls −23,000Unemployment 4.1%$SPY +3.51% on the week$QQQ +5.09%10y at 4.65%$USO −8.66%July CPI · Aug 12July PPI · Aug 13Retail sales · Aug 14

$SPYDaily market chart · referral applied only on click

SPY S and P 500 ETF daily stock chart August 2026

Executive summary · week ended August 7, 2026

A negative payroll print was the most bullish number of the week

Under a normal policy cycle, an economy that sheds 23,000 jobs in a month and revises away another 103,000 from the two months before would be a problem for equities. This is not a normal policy cycle. The Federal Open Market Committee held the target range at 3.50%–3.75% on July 29 by a 9–3 vote, and all three dissenters wanted a hike, not a cut. For most of the summer, the marginal risk priced into long-duration equities was that a strong labour market plus prices indices in the seventies would force the Committee to move again. July’s Employment Situation removed that risk in a single release, and the market repriced accordingly.

The scale of the move is worth stating precisely. The $SPY exchange-traded fund closed the week at $773.26 against $747.03 on July 31, a gain of 3.51%. $QQQ rose 5.09%, $DIA 2.92% and $IWM 3.56%. The S&P 500 index itself finished at a record close of 7,757.64 and the Nasdaq Composite at 26,690.62, the strongest week for the major averages since mid-April. Equal weight participated but lagged: $RSP gained 2.36%, a full 115 basis points behind the cap-weighted index, which tells you the rally was led from the top even though breadth was positive.

Underneath the index, the leadership was not what a simple rate-relief story would predict. Semiconductors gained 7.80% and technology 7.20%, which fits. But uranium gained 14.95%, rare earths 16.78%, silver 9.82% and gold 7.25%, while energy fell 3.44% and utilities 1.67%. That combination — long-duration technology and hard assets rising together, energy falling, the dollar slightly weaker — is the signature of a market lowering its expected path for policy rates while simultaneously keeping a hedge against the reason rates might have to stay high. Both trades were expressed at once, and the second one is the more interesting.

Treasuries confirmed the read without exaggerating it. The two-year fell from 4.28% to 4.19%, the ten-year from 4.75% to 4.65% and the thirty-year from 5.27% to 5.19%. Nine to ten basis points across the curve is meaningful relief, but it is not a repricing of the policy path; it is the removal of a hike that had been partially priced. The 2s10s spread finished at 46 basis points against 47 the week before, so the curve did not steepen materially. Duration got cheaper, but nobody has been paid yet for assuming the next move is down.

$SPY$773.26+3.51% on the week from $747.03. Record close for the underlying index.

$QQQ$723.03+5.09%. Nasdaq Composite finished at 26,690.62.

US 10-year4.65%Down 10bp from 4.75% on July 31. Two-year at 4.19%.

$USO−8.66%Crude gave back the Hormuz risk premium as OPEC+ completed its unwind.

The five things that actually mattered

Payrolls fell. Nonfarm payroll employment declined by 23,000 in July against an average monthly gain of 34,000 over the prior twelve months, with May and June revised down by a combined 103,000.
Wage growth cooled without collapsing. Average hourly earnings rose 2 cents to $37.62, up 3.2% over the year. That is the part of the report that lets the Committee treat the weakness as disinflationary rather than as a shock.
Services prices did not cooperate. The ISM Services prices index printed 70.3% in July, up 2.6 points from June and above 60% for the twentieth consecutive month. The labour market is loosening while the cost side is not.
Crude broke. OPEC+ confirmed a September increase of roughly 188,000 barrels a day, completing the unwind of the 2023 voluntary cuts, on top of the Iran diplomatic opening. $USO fell 8.66% on the week and energy was the worst sector.
Hard assets outran equities. Uranium, rare earths, silver and gold all beat the S&P 500 by a wide margin, in a week when the equity rally was supposedly about lower rates.

The July Employment Situation, read line by line

The Bureau of Labor Statistics released the July Employment Situation on Friday, August 7, at 08:30 Eastern. Total nonfarm payroll employment changed little in July at minus 23,000, following an average monthly gain of 34,000 over the prior twelve months. The unemployment rate was 4.1% and the number of unemployed people 6.9 million, both little changed on the month and over the year. Those are the headline numbers. The composition matters more than the headline, and it points in two directions at once.

Where the jobs were lost

Local government education shed 50,000 jobs after showing little net change over the prior twelve months. Retail trade lost 19,000, with warehouse clubs, supercenters and other general merchandise retailers down 21,000 and gasoline stations and fuel dealers down 5,000, partly offset by 10,000 added in sporting goods, hobby, musical instrument, book and miscellaneous retailers. Financial activities continued to trend down, losing 14,000 on the month through credit intermediation, down 9,000, and insurance carriers, down 7,000. Financial activities employment is now 121,000 below its recent peak of May 2025, which is one of the quieter multi-year trends in the current labour data.

Health care continued to add, at plus 22,000, but at a visibly slower pace than the 36,000 average monthly gain of the prior twelve months, with ambulatory health care services contributing 18,000. Every other major industry — mining, construction, manufacturing, wholesale trade, transportation and warehousing, information, professional and business services, social assistance, leisure and hospitality, other services — showed little change. A month in which the only reliable engine of job creation decelerates by nearly 40% and the losses are concentrated in public education and retail is a month that describes an economy running out of marginal hiring, not one falling off a cliff.

The revisions are the part that changes the trend

May was revised down by 66,000, from plus 129,000 to plus 63,000. June was revised down by 37,000, from plus 57,000 to plus 20,000. Combined, employment in those two months is 103,000 lower than previously reported. Taken together with July, the three-month run rate is now approximately plus 20,000 a month. That is a materially different economy from the one described by the initial prints, and it is the reason the market treated a single negative month as a trend confirmation rather than as noise.

There is a scheduled follow-up worth marking. On August 28 at 10:00 Eastern the BLS publishes the preliminary estimate of the annual benchmark revision to the establishment survey, benchmarked to the Quarterly Census of Employment and Wages for March 2026, on the same day the first-quarter QCEW data are issued. Official establishment survey estimates are not updated on the basis of that preliminary figure — the final revision arrives with the January 2027 release in February 2027 — but in each of the last several years the preliminary benchmark has moved the conversation about how much hiring actually took place.

Household survey: fewer people looking, not more people working

The unemployment rate held at 4.1%, but the labour force participation rate at 61.4% is down 0.7 percentage point since January and the employment-population ratio at 58.9% is down 0.5 point. A stable unemployment rate produced by a shrinking labour force is not the same signal as a stable rate produced by matched hiring. The number of people on temporary layoff rose by 153,000 to 921,000, while permanent job losers were little changed at 1.7 million. Long-term unemployed were 1.8 million, or 25.5% of all unemployed people. People employed part time for economic reasons were little changed at 4.8 million.

Wages: the number that made the report tradeable

Average hourly earnings for all private employees rose 2 cents to $37.62, up 3.2% over the year. For production and non-supervisory employees, earnings rose 4 cents to $32.40. The average workweek was unchanged at 34.3 hours, manufacturing at 40.4 hours, with factory overtime edging down 0.1 hour to 3.1 hours. A 3.2% annual pace of wage growth against a productivity trend of roughly 2% implies unit labour cost growth in the low single digits, and the preliminary second-quarter productivity release from the BLS on August 6 put non-farm productivity at plus 1.4% annualised and unit labour costs at plus 1.3%. Wage-driven inflation is not the argument the hawks on the Committee will be making in September.

Labour market indicator	Latest reading	Prior	Reading
Nonfarm payrolls, July	−23,000	+20,000 June (revised)	Prior 12-month average was +34,000. Three-month run rate now near +20,000.
Unemployment rate	4.1%	4.1%	Held flat, but participation fell to 61.4%, down 0.7pt since January.
Average hourly earnings	$37.62, +3.2% y/y	+2 cents m/m	Cooling without collapsing. The disinflationary read on the report.
May and June revisions	−103,000 combined	May 129k→63k, June 57k→20k	The revisions changed the trend, not just the month.
ADP private payrolls, July	+44,000	+95,000 June (revised)	Six-month low, released August 5. Annual pay for job-stayers +4.4%.
Initial jobless claims, week to Aug 1	199,000	198,000 revised	Four-week average 198,750, down 4,500. No layoff wave in the weekly data.
Continuing claims, week to Jul 25	1,801,000	1,777,000 revised	Up 24,000. Insured unemployment rate 1.2%. Hard to get hired, not easy to get fired.
Nonfarm productivity, Q2 preliminary	+1.4% annualised	+2.2% y/y	Unit labour costs +1.3% annualised. Manufacturing productivity +1.9%.

The two claims series together describe the labour market better than either alone. Initial claims at 199,000 with a four-week average of 198,750 say employers are not firing. Continuing claims at 1.801 million and rising say that people who do lose a job are taking longer to find the next one. That is the low-hire, low-fire equilibrium that has characterised this cycle, and July is the month in which the low-hire side finally tipped the net number below zero.

The Fed frame: this cycle has a hiking bias, not a cutting bias

Any reading of this week that starts from the assumption that weak data equals imminent rate cuts will misread what the market did. The Committee held the federal funds target range at 3.50%–3.75% on July 29 by a 9–3 vote, and the three dissenters preferred a 25 basis point increase. Kevin Warsh took office as Chairman of the Board of Governors on May 22, 2026 for a four-year term ending May 21, 2030, and chairs the FOMC. The next scheduled meeting is September 16.

That configuration explains why a negative payroll print produced a 5% week in the Nasdaq. What was being priced out was not the absence of a cut, which was never priced in; it was the presence of a hike, which had been building through a summer of ISM manufacturing at 55.6%, prices indices in the seventies and a second-quarter PCE price index that rose 5.1%. Market-implied odds of an unchanged rate in September rose sharply after the release, and the residual probability attached to a September increase fell to roughly the low forties, having been meaningfully higher a week earlier.

The problem for anyone extrapolating this into a durable easing narrative is the cost side. The ISM Services report on August 5 put the headline index at 54.1%, a twenty-fifth consecutive month of expansion, with business activity at 59.1% and new orders at 57.2%. The employment component fell 3.8 points to 47.4%, back into contraction, which corroborates the payroll data. The prices index, however, rose 2.6 points to 70.3%, above 60% for a twentieth consecutive month. Manufacturing told the same story a week earlier: an ISM headline of 55.6%, the strongest since May 2022, with a prices index at 71.1%.

A labour market that is softening while input prices sit above 70 on both sides of the economy is precisely the configuration that a committee with three hawkish dissenters will argue about for the whole of September. This is why the July CPI on Wednesday, August 12 and the July PPI on Thursday, August 13 carry more weight than they would in an ordinary month. The employment side of the mandate has now delivered its evidence. The price side has not.

Sessions in review: August 3 to August 7

All percentage moves below are computed on closing prices of the relevant exchange-traded funds, which is the cleanest verifiable series available for a same-week recap.

Monday, August 3: the oil move carried everything

$SPY closed at $757.67, up 1.42%, $QQQ at $700.07, up 1.76%, and $IWM at $296.22, up 1.72%. The proximate driver was energy. President Trump said he had cancelled planned strikes against Iran in favour of negotiations over reopening the Strait of Hormuz, and crude settled roughly 5% lower. Unlike most of July, the move was broad rather than concentrated: small caps kept pace with the index, which is the participation that had been missing while three or four megacaps carried the tape. The Dow closed at a record. The July ISM Manufacturing PMI, released the same morning, registered 55.6%, up 2.3 points from June and the strongest reading since May 2022, with production at 58.5%, new orders at 56.7% and the employment index at 52.8%, its first expansion reading in 33 months. Against that, the prices index was 71.1%.

Tuesday, August 4: semiconductors ran into the AMD print

$SPY closed at $771.33, up 1.80%, $QQQ at $723.85, up 3.40%, and $IWM at $301.71, up 1.85%. Palantir’s second-quarter release, out after the Monday close, was the single largest contributor to the session: revenue of $1.935 billion, up 93% year on year, with US commercial revenue of $764 million, up 149%, adjusted free cash flow of $1.220 billion and full-year guidance raised to $8.150–8.158 billion. The stock closed the session up roughly 29%. Semiconductors, the weakest part of the July tape, ran hard into the AMD report after the close. AMD delivered record revenue of $11.536 billion, up 50%, with data centre revenue of $6.718 billion, up 107%, non-GAAP diluted EPS of $1.66 and third-quarter guidance of about $13 billion. The stock finished the week up only 1.51%.

Wednesday, August 5: the first pause, and two regulatory decisions

$SPY slipped 0.20% to $769.79 and $QQQ fell 0.90% to $717.30. The ADP National Employment Report put private payrolls at plus 44,000 for July, a six-month low against expectations nearer 70,000, with June revised down to 95,000. The ISM Services report landed at 54.1% with employment back in contraction at 47.4% and prices up to 70.3%. On the corporate side, Eli Lilly reported second-quarter revenue of $23.0 billion, up 48%, with Mounjaro at $9.9 billion, up 91%, Zepbound US revenue at $4.9 billion, up 44%, adjusted EPS of $8.38 and full-year guidance raised to $85–87 billion of revenue and $35.50–36.50 of adjusted EPS. The FDA approved Moderna’s mFLUSIVA, the first mRNA-based seasonal influenza vaccine cleared in the United States, with traditional approval for adults 50 to 64 and accelerated approval for adults 65 and older. The same day, the agency approved Takeda’s Orzeyful for narcolepsy type 1. AST SpaceMobile launched BlueBird satellites 11, 12 and 13 from Cape Canaveral.

Thursday, August 6: consolidation ahead of payrolls

$SPY eased 0.16% to $768.56 and $QQQ fell 0.37% to $714.65. Weekly claims came in at 199,000 initial and 1.801 million continuing, and preliminary second-quarter productivity was reported at plus 1.4% with unit labour costs at plus 1.3%. Replimune received FDA accelerated approval for Tudriqev in combination with nivolumab for advanced cutaneous melanoma after progression on anti-PD-1 therapy, on an objective response rate of 24.2% in 91 evaluable patients with a median duration of response of 14.1 months, at a list price of $450,000 per course. It was the company’s third submission after two prior refusals. Iovance reported second-quarter revenue of roughly $99.3 million, up 66% year on year, with US Amtagvi revenue near $91 million against guidance of $79–81 million, and more than 95 authorised treatment centres. Novavax reported revenue of $57 million, down 76% year on year against a prior-year quarter that included a $175 million milestone, with a net loss of $53 million and $724 million of cash and investments. Centrus Energy signed a definitive supply agreement with X-energy, taking its backlog to $4.5 billion. MP Materials reported second-quarter revenue of $108.49 million.

Friday, August 7: the payroll print and the record close

$SPY rose 0.61% to $773.26, $QQQ 1.17% to $723.03 and $IWM 1.11% to $301.56, taking the S&P 500 to a record close of 7,757.64 and the Nasdaq Composite to 26,690.62. The July Employment Situation was the entire session. Treasury yields fell across the curve, with the two-year at 4.19%, the ten-year at 4.65% and the thirty-year at 5.19%. Bloomberg reported that the US Army would spend at least $400 million on AeroVironment’s Locust counter-drone laser systems, the first production contract for a directed-energy counter-drone weapon; $AVAV finished the week up 25.01%. Oklo reported second-quarter revenue of $1.2 million with a net loss of $48.5 million and $3.0 billion of liquidity, alongside first criticality of its Groves isotope reactor.

Cross-asset market map

Weekly changes computed on closing prices from July 31 to August 7, 2026.

Instrument	Aug 7 close	Week	What it says
$SPY · S&P 500	$773.26	+3.51%	Record close on the underlying index. Best week since mid-April.
$QQQ · Nasdaq 100	$723.03	+5.09%	Long duration led. Rate relief plus the Palantir read-through.
$DIA · Dow	$539.62	+2.92%	Participated, but this was not a value-led week.
$IWM · Russell 2000	$301.56	+3.56%	Kept pace with the index. Small caps need the front end to fall, and it did.
$RSP · equal weight	$220.09	+2.36%	115bp behind cap weight. Breadth was positive but leadership was narrow.
$SMH · semiconductors	$582.70	+7.80%	Best major industry group. AMD beat did not carry it; the rate move and Nvidia did.
$XLK · technology	$187.97	+7.20%	Best S&P sector by a wide margin.
$XBI · biotech	$157.37	+7.05%	Two approvals inside 48 hours plus a 10bp fall in the ten-year.
$IBB · large-cap biotech	$197.71	+6.06%	The move was not confined to speculative small caps.
$ITA · aerospace and defence	$250.75	+4.63%	Contract news at the small-cap end pulled the group.
$XLB · materials	$52.86	+4.82%	Dragged up by the metals complex rather than by chemicals.
$XLY · consumer discretionary	$119.86	+3.25%	Ahead of a retail sales print and the retail earnings season.
$XLI · industrials	$185.18	+2.97%	In line with the index.
$XLC · communication services	$111.25	+2.78%	Slightly behind the index despite the technology bid.
$XLV · health care	$165.68	+1.93%	Well behind $XBI. The large-cap pharma complex did not lead.
$XLF · financials	$57.60	+1.16%	Regional banks flat at +0.20% on $KRE. A falling front end is not automatically good for banks.
$XLP · staples	$85.12	+0.08%	Effectively unchanged. Defensives were the funding source.
$XLRE · real estate	$44.98	−0.20%	Notable: 10bp of rate relief did not lift real estate.
$XLU · utilities	$43.61	−1.67%	Sold as a bond proxy even as bonds rallied.
$XLE · energy	$57.50	−3.44%	Worst sector. Followed crude down.
$USO · crude oil fund	$117.98	−8.66%	Hormuz premium removed plus the OPEC+ September increase.
$GLD · gold	$398.47	+7.25%	Best week since January according to contemporaneous reporting.
$SLV · silver	$57.50	+9.82%	Outran gold, as it usually does when the move is flow-driven.
$URA · uranium	$44.91	+14.95%	Company news across Oklo, Centrus and the wider fuel-cycle complex.
$REMX · rare earths	$77.04	+16.78%	Best-performing theme on the board.
$ARKK	$79.43	+11.50%	The clearest single expression of the duration trade.
$TLT · long Treasuries	$82.76	+0.62%	Bonds rallied, but modestly. Eight basis points on the long bond.
$UUP · dollar	$28.07	−0.35%	Softer, which is part of the gold story but not the whole of it.

What would confirm the move

July CPI on August 12 lands at or below expectations on the core measure, so the labour-market evidence is not immediately contradicted by the price side.
PPI on August 13 does not corroborate the 70.3% ISM services prices reading.
$RSP and $IWM keep pace with $SPY through the CPI print instead of handing leadership straight back to megacap technology.
The ten-year holds at or below 4.65% after the inflation data rather than retracing the whole weekly move.
Retail sales on August 14 show the consumer intact, which would let the market read the payroll weakness as normalisation rather than as the start of something.

What would break it

A hot core CPI, which would restore the September hike debate with a labour market already weakening — the least comfortable combination for equities.
The Iran channel closing again, which would put the risk premium straight back into crude and, through it, into headline inflation.
Retail sales missing badly, turning a disinflation story into a demand story.
Continuing claims accelerating above the recent range in Thursday’s report, which would move the labour discussion from cooling to contracting.
Equal weight and small caps rolling over while $QQQ makes new highs, which would mean the week was a duration trade and nothing more.

The hard-asset trade was bigger than the equity trade

An index up 3.51% is the headline. It is not where the money was made. Rare earths gained 16.78%, uranium 14.95%, silver 9.82% and gold 7.25%, and inside those baskets several individual names moved more than twice the index. $MP Materials rose 23.54%, Barrick rose 18.92%, Franco-Nevada 12.08% and Centrus Energy 8.16%. This deserves separating from the rate story because the two explanations do not fully overlap.

Precious metals: rates, dollar and something else

Two thirds of the gold move has a clean explanation. Nominal yields fell across the curve, the dollar softened modestly, with $UUP down 0.35%, and crude fell hard, which lowers near-term inflation expectations and therefore raises real yields only if nominal yields hold — they did not. Lower nominal yields plus a softer dollar is the textbook setup for bullion. What that does not explain is why silver outperformed gold by more than 250 basis points, or why the move was the strongest since January. Silver leading gold generally indicates flow and momentum rather than a pure macro hedge. Both interpretations can be true at once, and the honest position is that the reserve-asset bid of the past two years has not gone away and does not require a weekly catalyst to reassert itself.

Uranium and the nuclear fuel cycle

The uranium move was carried by company-specific news rather than by a new federal action. Centrus Energy signed a definitive agreement with X-energy on August 6 for low-enriched and high-assay low-enriched uranium supporting the Xe-100 reactor programme and TRISO-X fuel, with advance payments toward domestic commercial enrichment capacity, lifting backlog to $4.5 billion. Oklo reported first criticality of its Groves isotope reactor and Department of Energy acceptance of the preliminary documented safety analysis for Aurora at Idaho National Laboratory, alongside second-quarter revenue of $1.2 million, a net loss of $48.5 million and $3.0 billion of liquidity. Neither of those is a policy event; both are execution milestones in a sector that has been priced on policy for two years. The distinction matters, because execution milestones are repeatable and policy headlines are not.

Rare earths and the supply-chain premium

$REMX at plus 16.78% was the strongest theme on the board, and the cleanest verified company data point inside it was MP Materials’ second-quarter revenue of $108.49 million, reported August 6 and above the consensus figure carried by the data providers. The structural backdrop — Chinese export controls on rare-earth elements and the tightening of enforcement through 2026, against a Department of Defense arrangement with MP Materials that includes a price floor on NdPr and a multi-year offtake — has been in place for months. What changed this week was not the policy but the willingness to pay for it, which is what happens to supply-chain themes when the discount rate falls.

Crude went the other way, and that is the link

$USO fell 8.66%. Two things happened at once. The eight OPEC+ producers confirmed a September output increase of roughly 188,000 barrels a day, completing the unwind of the 1.65 million barrel a day voluntary cuts first imposed in 2023, with the next meeting scheduled for September 6. And the Iran diplomatic opening removed the Strait of Hormuz premium that had been embedded in the price since the spring. A falling oil price is disinflationary at the headline, which is part of why the market was willing to treat a weak payroll report as good news rather than as a growth scare. It is also why the ISM services prices index at 70.3% is the uncomfortable number: if headline inflation is falling because of energy while services costs keep rising, the composition of the CPI print on Wednesday matters more than the level.

Earnings review: what was proved this week

Ticker	Reported	Verified numbers	Week	Read-through
$PLTR	Aug 3, after close Aug 2	Revenue $1.935bn, +93% y/y. US commercial $764m, +149%; US government $809m, +90%. Adjusted EPS $0.41. Closed TCV $3.373bn, +49%. FY26 guidance raised to $8.150–8.158bn revenue and $4.5–4.7bn adjusted free cash flow.	+39.78%	The single largest contributor to the week’s AI complex. It also raises the bar for every AI-adjacent name reporting after it.
$AMD	Aug 4, after close	Record revenue $11.536bn, +50% y/y. Data Center $6.718bn, +107%, now 58% of revenue. Non-GAAP EPS $1.66. Gross margin 54%. Q3 guidance about $13bn.	+1.51%	A 50% revenue increase produced a 1.5% week. The stock had run into the print and the market is now paying for the second half, not for the quarter just delivered.
$LLY	Aug 5	Revenue $23.0bn, +48%. Mounjaro $9.9bn, +91%. Zepbound US $4.9bn, +44%. Adjusted EPS $8.38. FY26 guidance raised to $85–87bn revenue and $35.50–36.50 adjusted EPS.	—	The metabolic franchise is still compounding at a rate that reframes the whole large-cap pharma group.
$IOVA	Aug 6	Revenue about $99.3m, +66% y/y and +39% sequentially. US Amtagvi about $91m against $79–81m guidance. Gross margin 56%. More than 95 authorised treatment centres, target at least 110 by year end. FY26 guidance of $350–370m under review after stronger demand.	—	One of the few clean commercial-execution reads in cell therapy, and it beat its own guidance rather than a sell-side number.
$NVAX	Aug 6	Revenue $57m, −76% y/y against a prior-year quarter containing a $175m milestone. Net loss $53m against net income of $107m. Cash and investments $724m at June 30.	—	A milestone-driven revenue line makes year-on-year comparisons close to meaningless. The cash position and the Sanofi technology transfer are the operative variables.
$OKLO	Aug 7	Revenue $1.2m, first revenue reported. Net loss $48.5m against $24.7m a year earlier. Liquidity $3.0bn. First criticality of the Groves isotope reactor; DOE acceptance of the preliminary documented safety analysis for Aurora-INL.	+24.70%	Priced on milestones, not on the income statement. With $3.0bn of liquidity the financing question is off the table for now, which is unusual in this group.
$MP	Aug 6	Revenue $108.49m, above the consensus figure carried by data providers.	+23.54%	The clearest fundamental data point inside the strongest theme of the week.
$LEU	Aug 5–6	Q2 revenue $176.1m, +14% y/y. Definitive supply agreement with X-energy for LEU and HALEU, with advance payments toward domestic enrichment capacity. Backlog $4.5bn.	+8.16%	Backlog conversion is what separates the fuel-cycle names from the reactor concepts.

Contract awards moved more than earnings did

Three of the five largest single-name moves in the coverage universe came from government awards rather than from quarterly results. Rocket Lab received a $397 million contract from the US Space Force under the Space-Based Airborne Moving Target Indicator programme on August 4, to build, launch and operate Flatellite satellites on the Neutron vehicle, one week after a $266 million missile-defence award; the stock gained 27.53% and the company completed its thirteenth Electron launch of the year on August 6. AeroVironment gained 25.01% on the reported $400 million US Army order for Locust counter-drone laser systems, the first production-stage contract for a directed-energy counter-drone weapon rather than a prototype award. AST SpaceMobile gained 21.97% on the successful launch of BlueBird 11, 12 and 13, which roughly double peak download speed relative to the first-generation satellites, with production reaching the forty-second spacecraft.

The pattern is consistent: in this part of the market the tape is currently paying for signed government demand and for hardware that exists, and paying much less for revenue growth that was already expected. AMD grew revenue 50% and gained 1.51%. Rocket Lab announced a contract and gained 27.53%.

Verified event calendar: August 10 to August 14

Macroeconomic dates below are taken from the official release schedules of the Bureau of Labor Statistics, the Census Bureau and the University of Michigan Surveys of Consumers. Earnings dates are those confirmed by company investor-relations announcements, with the two exceptions flagged in the table. All times are Eastern.

Date	Event	Tickers and assets	What the market will trade
Mon, Aug 10	No scheduled top-tier macro release. Earnings: Barrick Mining before the open; Rocket Lab, AST SpaceMobile (call 17:00) and Archer Aviation after the close; AECOM after the close.	$B $RKLB $ASTS $ACHR $ACM $ITA $URA	Three of the four largest movers of the past week report on the same evening. After a 27% and a 22% week respectively, $RKLB and $ASTS are reporting into expectations that have already moved. Barrick reports into a gold price at multi-week highs.
Tue, Aug 11	No scheduled top-tier macro release. Earnings: Cardinal Health, Sea Limited, Tencent Music, On Holding and Elbit Systems before the open; Super Micro Computer (17:00), Franco-Nevada and Legend Biotech after the close or on call. Lithium Argentina before the open.	$CAH $SE $TME $ONON $ESLT $SMCI $FNV $LEGN $LAAC	Super Micro is the AI-infrastructure read of the week after its preliminary business update. Legend Biotech frames the CAR-T commercial story. Elbit is the European and Israeli defence comparison to the US primes.
Wed, Aug 12	July Consumer Price Index, 08:30, with Real Earnings for July at the same time. Census Business Formation Statistics. Earnings: Cisco after the close at 16:30; Brinker International before the open; EnerSys after the close.	$SPY $QQQ $IWM $TLT $GLD $CSCO $EAT $ENS	The most important number of the week. The labour side of the mandate has already reported; this is the price side. With ISM services prices at 70.3%, the core services composition matters more than the headline, which energy will flatter.
Thu, Aug 13	July Producer Price Index, 08:30. Weekly jobless claims, 08:30. Earnings: Applied Materials after the close at 16:30; JD.com before the open.	$AMAT $SMH $JD $SPY $TLT	PPI either corroborates or contradicts the services prices reading from ISM. Applied Materials is the capital-equipment confirmation of the semiconductor cycle, reporting into a group that gained 7.80% last week.
Fri, Aug 14	Advance Retail and Food Services Sales for July, 08:30 (Census). Business Inventories for June, 10:00. University of Michigan preliminary August consumer sentiment, 10:00. Earnings: Vipshop before the open.	$XLY $XRT $SPY $VIPS consumer	June advance retail sales were $768.6 billion, up 0.2%. After a negative payroll month the consumer print carries more weight than usual. The Michigan release also updates one-year inflation expectations, last at 4.2%, and the five-year measure, last at 3.3%.

Two dates just outside the window that are already shaping positioning

August 18 to 20: the large US retailers report, with Home Depot on August 18, Target on August 19 and Walmart and Deere on August 20. The mid-August retail season falls the week after this one, not during it.
August 26 and August 28: Nvidia’s quarterly results on August 26, and on August 28 at 10:00 the BLS preliminary benchmark revision to the establishment survey for March 2026, published alongside first-quarter QCEW data. In a market that has just repriced on payroll revisions, the preliminary benchmark is a genuine event risk.

The September FOMC meeting is on September 16. Between now and then the Committee sees this week’s CPI and PPI, the August Employment Situation on September 4 and the August CPI on September 11.

Biotech catalyst pulse

Biotech had its best week in months, with $XBI up 7.05% and $IBB up 6.06%, and for once the sector move had two identifiable causes rather than one. Rates fell across the curve, which lowers the discount rate applied to pre-revenue cash flows, and the FDA approved two products in 48 hours after a period in which the agency’s selectivity had been the sector’s dominant narrative.

What was decided this week

Ticker	Decision	Terms	Week
$REPL	FDA accelerated approval of Tudriqev (vusolimogene oderparepvec-wtpg) with nivolumab, August 6	Advanced unresectable cutaneous melanoma after progression on anti-PD-1. Objective response rate 24.2% in 91 evaluable patients, median duration of response 14.1 months. List price $450,000 per course. Third submission after two prior refusals; the advisory committee had voted 10–3 on July 30 that the IGNYTE data were evaluable and clinically meaningful.	+7.68%
$MRNA	FDA approval of mFLUSIVA (mRNA-1010), August 5	First mRNA-based seasonal influenza vaccine approved in the United States. Traditional approval for adults 50 to 64, accelerated approval for adults 65 and older with confirmatory work ongoing. Supported by a trial of more than 40,000 adults aged 50 and over. Expected availability for the 2026–2027 respiratory season.	—
Takeda	FDA approval of Orzeyful (oveporexton), August 5	First treatment addressing the full range of narcolepsy type 1 symptoms, an orexin receptor agonist, cleared under Breakthrough Therapy designation and Priority Review, pending DEA scheduling.	—

What is still ahead

Date	Ticker and event	Status	Risk frame
Aug 17–20	CHMP plenary meeting, European Medicines Agency	Confirmed on the EMA published meeting calendar for 2026.	European opinions rarely move US small caps on the day, but they set the timeline for EU revenue in any dual-track filing.
Aug 22	$CAPR — PDUFA for deramiocel (BLA) in Duchenne muscular dystrophy cardiomyopathy	Date unchanged. The Cell, Tissue and Gene Therapies advisory committee voted 3–9 against the efficacy evidence on July 29.	Very high and binary, with an adverse panel going in. The financing position behind either outcome is as important as the decision itself. $CAPR gained 6.23% last week.
Aug 22	$SVRA — PDUFA for MOLBREEVI (BLA, priority review) in autoimmune pulmonary alveolar proteinosis	Company communication indicates no advisory committee was planned. Verify against the company’s own filings before the date.	High. A rare-disease first-in-class filing with no panel is a cleaner regulatory setup than $CAPR, but a single-product outcome nonetheless. $SVRA gained 6.78%.
Aug 25	$ZYME — PDUFA for zanidatamab (sBLA), first-line HER2-positive gastro-oesophageal adenocarcinoma	Confirmed in the company’s corporate update of August 6, which also covered second-quarter results and the pending Theravance Biopharma acquisition.	High but supported by a label expansion rather than a first approval. $ZYME gained 7.29%.
Sep 12–15	IASLC World Conference on Lung Cancer, Seoul	Confirmed on the official congress calendar.	The main data venue of the period for thoracic oncology.
Sep 14–17	CHMP plenary meeting	Confirmed on the EMA calendar.	The September opinions are the ones that determine European launches inside the current year.
Sep 23	FDA Molecular and Clinical Genetics Panel on GRAIL’s Galleri multi-cancer blood test (PMA)	Confirmed by Federal Register notice, docket FDA-2026-N-8004.	The first advisory committee of the autumn with implications well beyond a single company, since it addresses the evidentiary standard for multi-cancer early detection.

One correction worth carrying forward, because it appears wrongly on several third-party catalyst calendars: the Praxis Precision Medicines PDUFA for relutrigine, previously listed for September 27, 2026, was extended by three months to December 27, 2026 following a major amendment, as disclosed in the company’s Form 8-K of June 29. It is no longer a September event.

Operational watchlist for the week ahead

This is an event map, not a buy list. In every row, what is worth observing is the reaction after the catalyst rather than the headline itself.

Bucket	Tickers	Trigger to monitor	What would confirm the current setup
Broad market	$SPY $QQQ $RSP $IWM	July CPI on Aug 12, PPI on Aug 13, retail sales on Aug 14	Equal weight and small caps keep pace with the cap-weighted index through the inflation prints instead of giving leadership back to megacap technology within a session.
Rates	$TLT 2-year 10-year 30-year	Whether the 10-year holds 4.65% after CPI	The curve keeps the relief it took last week rather than retracing it in one session, and 2s10s does not flatten back toward 40bp.
Semiconductors	$AMAT $SMH $NVDA $SMCI	Super Micro on Aug 11 and Applied Materials on Aug 13	The group holds a 7.80% week through two of its own reports. Capital equipment confirming the cycle matters more than another design win.
Space and defence	$RKLB $ASTS $ACHR $AVAV $ESLT $ITA	Three reports on the evening of Aug 10 after a week of 20% to 27% moves	Backlog converting into recognised revenue, and dispersion inside the group rather than uniform sympathy moves.
AI software	$PLTR $BBAI $AI	Whether the Palantir read-through survives a full week	Sector sympathy still visible after the initial reaction has faded, and second-tier names holding gains without a company-specific catalyst.
Nuclear and uranium	$OKLO $LEU $URA	Execution milestones, DOE actions and fuel contracts	Backlog and signed offtake rather than announcements of intent. $LEU converting its X-energy agreement into recognised revenue is the test.
Rare earths and critical minerals	$MP $REMX $LAAC	Chinese export-control enforcement, NdPr pricing, Lithium Argentina results on Aug 11	The theme holds a 16.78% week without a new policy headline, which would suggest the bid is fundamental rather than narrative-driven.
Precious metals	$GLD $SLV $B $FNV	Barrick on Aug 10, Franco-Nevada on Aug 11, real yields after CPI	Miners keeping pace with metal, and gold holding its gain if the CPI print pushes nominal yields back up.
Biotech	$XBI $CAPR $SVRA $ZYME $IOVA $LEGN	Legend Biotech on Aug 11, three PDUFA dates between Aug 22 and Aug 25	$XBI stops trading purely as a duration proxy and keeps pace on days when rates are flat.
Energy	$USO $XLE	Hormuz diplomacy, physical flows, the OPEC+ meeting on Sep 6	Crude stabilising without a new escalation headline, which would suggest physical rather than headline-driven pricing.
Consumer	$XLY $ONON $EAT $VIPS	Retail sales on Aug 14 and the retail reporting season the following week	The discretionary complex holding up into a print that follows a negative payroll month.

Three scenarios into Friday, August 14

Constructive

Core CPI on Wednesday lands at or below expectations, PPI on Thursday does not corroborate the 70.3% ISM services prices reading, and retail sales on Friday show a consumer that is spending. In that configuration the labour-market weakness reads as normalisation rather than as the beginning of a contraction, the September hike debate closes, the ten-year holds below 4.65% and the breadth of last week extends rather than narrows. Small caps, biotech and the rate-sensitive parts of the market lead, and the hard-asset trade continues alongside rather than instead of the equity trade.

Mixed, and the base case

Headline inflation is flattered by energy while core services stay firm, so the print settles nothing for September. Yields chop within the range established last week, the index holds while leadership rotates, and single-name catalysts dominate: the space and defence reports on Monday evening, Super Micro on Tuesday, Applied Materials on Thursday. The three PDUFA dates between August 22 and August 25 start to be positioned for. In this scenario the weekly index change is small and the dispersion inside it is large, which is the environment the past six weeks have already been describing.

Adverse

Core CPI comes in hot and PPI confirms it. That would put a September increase back on the table with a labour market that has just printed a negative month, which is the least comfortable combination available: tightening into weakness. The whole of last week’s curve relief would be at risk, and the sectors that gained most from it — $QQQ, $ARKK, $XBI, small caps — would give back the most. A second version of the adverse case does not require inflation at all: a badly missed retail sales number on Friday would turn the disinflation story into a demand story, at which point falling yields stop helping equities because they are falling for the wrong reason. Watch continuing claims on Thursday for the early read on that.

Core Merlintrader hubs for the week ahead

Verification sources and transparency note

Economic release dates and figures are taken from the publishing agency. Index and exchange-traded fund levels are closing prices from Finviz Elite. Treasury yields are constant maturity rates published by the US Treasury. Company figures are taken from company releases or SEC filings.

What could not be verified for this edition

The closing level of the VIX on August 7 could not be confirmed against a primary source and is therefore not quoted. Contemporaneous reporting described the index as having fallen to its lowest level since January 2026.
Two of the earnings dates in the week-ahead table, AECOM on August 10 and EnerSys on August 12, are carried by data providers as confirmed but no company investor-relations announcement was located for either. They are marked here as probable rather than confirmed.
The Savara PDUFA date of August 22 was reported through secondary channels citing the company’s own communication rather than read directly from the company’s filings. It should be checked against the company’s disclosures ahead of the date.
A specific week-of cause could not be established for the 11.86% weekly gain in $LEGN, which reports on August 11 and had no company announcement dated within the week. The move is described here without an attributed cause.
Reports of a broad US tariff action taking effect on August 7, 2026 could not be confirmed against the Federal Register or an official White House action and are not included in this edition.

Educational disclaimer: This page is published for informational and educational purposes only. It does not constitute investment advice, financial advice, legal advice, a recommendation, an offer or a solicitation to buy or sell any security, and it is not a personalised recommendation of suitability for any individual. Merlintrader is not a registered investment adviser or broker-dealer under the rules of the US Securities and Exchange Commission. Equities, biotech catalysts and small-capitalisation stocks are volatile instruments that can result in the partial or total loss of invested capital. Past performance is not indicative of future results. Readers should verify all material events against primary sources and consult a licensed financial professional before making any investment decision.

Get the next Weekly Pulse in real time

Join the Merlintrader Telegram channel for market recaps, biotech catalyst updates and Stock Hub refreshes as soon as they go live.

Join @merlintraderpub_com on Telegram

Free Biotech Catalyst Calendar

Track upcoming PDUFA dates, FDA advisory committees, clinical readouts and regulatory decisions in one place, updated continuously and free to access.

Open the Biotech Catalyst Calendar

Real-Time Market Scanner

Professional Trading Workflow